Retina UK: Gene therapy for RPE65 gene approved for use in EU

23 November 2018
Source: Retina UK

The gene therapy Luxturna has won European regulatory approval for the treatment of

Retina UK logo

Inherited retinal dystrophy caused by mutations in the RPE65 gene. This milestone decision was made by the European Medicines Agency (EMA) on Thursday, 22 November.
Luxturna is the first and only gene therapy available in Europe to treat inherited retinal disease. It had already been approved for use by the FDA in the United States.

There will now be significant discussions at national level to determine pricing and access to the treatment before it is made available to patients. The timeline for this is difficult to predict.
The RPE65 gene provides instructions for building an enzyme that is critical for recycling the substances that convert light into electrical signals at the back of the eye. If this enzyme is reduced or absent because of genetic mutations, the visual cycle is blocked, resulting in impaired vision and the accumulation of toxins.

Vision loss often starts during childhood or adolescence and progresses as retinal cells degenerate. Fifty percent of people with mutations in both their copies of the RPE65 gene (one copy is inherited from each parent) will experience severe sight loss by the time they are 16 years old.

The EMA has approved Luxturna for patients who have two mutated copies of RPE65 and still have sufficient viable retinal cells, as determined by an ophthalmologist, to benefit from the therapy. Luxturna works by delivering healthy, functional copies of the RPE65 gene, via a single retinal injection, to restore levels of the enzyme and allow the visual cycle to progress normally. As demonstrated in clinical trials, this can prevent further vision loss and can restore some functional vision; patients treated with Luxturna showed significantly improved night vision one year after treatment.

“This is a milestone decision and one that provides huge hope for those who live with inherited retinal conditions,” said Tina Houlihan, Chief Executive of Retina UK

Read the full report on the Retina UK Website

Related Posts